AVTR vs. BIO: Avantor vs. Bio-Rad Laboratories Stock Comparison
How do Avantor (AVTR) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Bio-Rad Laboratories (BIO) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | AVTR | BIO |
|---|---|---|
| Name | Avantor, Inc. | Bio-Rad Laboratories Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.48 billion USD | 10.26 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | February 27, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Total Return (1Y) | 36.41% | 28.31% |
| Total Return (3Y, Annualized) | -5.02% | 8.52% |
| Total Return (5Y, Annualized) | -16.62% | -11.74% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 36.50% |
| Beta (5Y) | 0.94 | 1.03 |
| Max Drawdown (5Y) | -82.42% | -72.24% |
| Avg. Volume (3M) | 8.56M | 250.78K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.66 |
| Sortino Ratio (1Y) | 1.17 | 0.98 |
Profitability
ROE (TTM)
Bio-Rad Laboratories (BIO) at 14.27% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for BIO.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Avantor (AVTR) at 8.19% and Bio-Rad Laboratories (BIO) at 11.82% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | BIO |
|---|---|---|
| ROE (TTM) | 5.91% | 14.27% |
| ROA (TTM) | 2.83% | 1.50% |
| Net Margin (TTM) | 5.08% | 39.45% |
| Operating Margin (TTM) | 8.19% | 11.82% |
| Gross Margin (TTM) | 31.59% | 52.19% |
Growth
Revenue Growth
Bio-Rad Laboratories (BIO) at 0.65% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 0.65% |
| Revenue Growth (3Y CAGR) | -4.46% | -2.68% |
| EPS Growth (YoY) | -175.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Bio-Rad Laboratories (BIO) at 0.18 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 3.18 |
| Debt / Equity (MRQ) | 0.63 | 0.18 |
| Net Debt / EBITDA | 3.40 | -0.73 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | BIO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Avantor (AVTR) at 30.94 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Avantor (AVTR) at 1.80 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | BIO |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 10.14 |
| P/S Ratio (TTM) | 1.58 | 3.96 |
| P/B Ratio (MRQ) | 1.80 | 1.35 |
| Free Cash Flow Yield (TTM) | 4.21% | 2.65% |